

Figure 8 | Effect of mepenzolate on heart rate. Mice were administered indicated doses of mepenzolate intratracheally (a), orally (b), intravenously (c) or intrarectally (d). The alteration of heart rate (beats per minute) by the mepenzolate administration was monitored as described in the Materials and Methods. Mepenzolate-dependent alteration of heart rate from the baseline to the peak is shown. Values represent mean \pm S.E.M. (n5 30). * P, 0.05; ** P, 0.01.

For measurement of methacholine-induced increases in airway resistance, mice were exposed to nebulized methacholine (1 mg/ml) five times for 20 sec with a 40 sec interval, and airway resistance was measured after each methacholine challenge by the snapshot technique. All data were analysed using the FlexiVent software.

Determination of the FEV_{0.05}/FVC (forced expiratory volume in the first 0.05 seconds to forced vital capacity) ratio was performed with the same computer-controlled small-animal ventilator connected to a negative pressure reservoir (SCIREQ,

Montreal, Canada), as described previously^{18,19}. Mice were tracheotomised and ventilated as described above. The lung was inflated to 30 cmH₂O over one second and held at this pressure. After 0.2 sec, the pinch valve (connected to ventilator) was closed and after 0.3 sec, the shutter valve (connected to negative pressure reservoir) was opened for exposure of the lung to the negative pressure. The negative pressure was held for 1.5 sec to ensure complete expiration. FEV_{0.05}/FVC was determined using the FlexiVent software.

Table 1 | Efficacy versus toxicity ratio for different routes of mepenzolate administration

Administration route	Intratracheal	Oral	Intravenous	Intrarectal
Efficacy	38 μ g/kg	190 mg/kg	10 μ g/kg	1.5 mg/kg
Toxicity	4700 μ g/kg	7.5 mg/kg	10 μ g/kg	1.5 mg/kg
Toxicity/Efficacy	120	0.04	1	1

The effective dose (efficacy) was determined as the minimum dose required to significantly suppress the PPE-induced increase in MLI (Figs. 1c, 2c, 3c and 5c). The toxic dose (toxicity) was determined as the minimum dose required to significantly affect either fecal pellet output or heart rate (Figs. 7 and 8). The ratio of the toxic dose versus the effective dose for each route of administration is shown.

Analysis of fecal pellet output. Mice were subjected to restraint stress by being placed individually into a 50 ml tube (Becton Dickinson, Franklin Lakes, NJ) for 1 h, as described previously²⁸. These tubes are small enough to restrain a mouse so that it is able to breathe but unable to move freely. The number of fecal pellets excreted during the restraint stress period (1 h) was measured.

Measurement of heart rate. Heart rate was measured with a MouseOx system (STARR Life Sciences Corp., Allison Park, PA), as described previously²⁹. Mice were anesthetized with chloral hydrate (500 mg/kg) and the sensor was attached to the thigh. Heart rate was determined using MouseOx software (STARR Life Sciences Corp., Allison Park, PA).

Determination of the level of mepenzolate in vivo. After administration of mepenzolate, blood samples (800 µl) were taken periodically into centrifuge tubes containing heparin (50 µl) and centrifuged immediately (1000 g, 10 min) to obtain the sample. Whole lungs were taken from mepenzolate-treated mice, homogenised in sterile PBS containing 50 U/ml heparin, and centrifuged (14,000 g, 1 min) to obtain the sample. An aliquot (300 µl) of each sample was ultrafiltered with an Amicon ultra-0.5 centrifugal filter to extract the mepenzolate. The filtrate was analysed by analytical HPLC with a reverse-phase column (TSKgel Super-ODS, 150 × 4.6 mm, 2 µm, Tosoh Co., Tokyo, Japan), Waters 2695 Alliance separation module, and a Waters 2996 photodiode array detector (Waters, Milford, MA). Solution containing 30% (v/v) acetonitrile and 14 mM potassium dihydrogen phosphate/sodium 1-propanesulfonate buffer was used at a flow rate of 0.3 ml/min. Detection was performed at an optical density of 220 nm.

Statistical analysis. All values are expressed as the mean ± S.E.M. Two-way ANOVA followed by the Tukey test or the Student's t-test for unpaired results was used to evaluate differences between three or more groups or between two groups, respectively. Differences were considered to be significant for values of $P < 0.05$.

1. Rabe, K. F. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* **176**, 532–555 (2007).
2. Barnes, P. J. & Stockley, R. A. COPD: current therapeutic interventions and future approaches. *Eur Respir J* **25**, 1084–1106 (2005).
3. Owen, C. A. Proteinases and oxidants as targets in the treatment of chronic obstructive pulmonary disease. *Proc Am Thorac Soc* **2**, 373–385; discussion 394–375 (2005).
4. Tashkin, D. P. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. *N Engl J Med* **359**, 1543–1554 (2008).
5. Calverley, P. M. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med* **356**, 775–789 (2007).
6. Alsaedi, A., Sin, D. D. & McAlister, F. A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. *Am J Med* **113**, 59–65 (2002).
7. Barnes, P. J., Ito, K. & Adcock, I. M. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. *Lancet* **363**, 731–733 (2004).
8. Mizushima, T. Drug discovery and development focusing on existing medicines: drug re-profiling strategy. *J Biochem* **149**, 499–505 (2011).
9. Tanaka, K. et al. Mepenzolate bromide displays beneficial effects in a mouse model of chronic obstructive pulmonary disease. *Nat Commun* **4**, (2013).
10. Chen, J. Y. Antispasmodic activity of JB-340 (N-methyl-3-piperidyl-diphenylglycolate methobromide) with special reference to its relative selective action on the sphincter of Oddi, colon and urinary bladder of the dog. *Arch Int Pharmacodyn Ther* **121**, 78–84 (1959).
11. Buckley, J. P., De, F. J. & Reif, E. C. The comparative antispasmodic activity of N-methyl-3-piperidyl diphenylglycolate methobromide (JB-340) and atropine sulfate. *J Am Pharm Assoc Am Pharm Assoc (Baltim)* **46**, 592–594 (1957).
12. Long, J. P. & Keasling, H. H. The comparative anticholinergic activity of a series of derivatives of 3-hydroxy piperidine. *J Am Pharm Assoc Am Pharm Assoc (Baltim)* **43**, 616–619 (1954).
13. Drummond, G. R., Selemidis, S., Griendling, K. K. & Sobey, C. G. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. *Nat Rev Drug Discov* **10**, 453–471 (2011).
14. Gosker, H. R. et al. Altered antioxidant status in peripheral skeletal muscle of patients with COPD. *Respir Med* **99**, 118–125 (2005).
15. Rahman, I. & MacNee, W. Antioxidant pharmacological therapies for COPD. *Curr Opin Pharmacol* **12**, 256–265 (2012).
16. Prat, M., Gavalda, A., Fonquerna, S. & Miralpeix, M. Inhaled muscarinic antagonists for respiratory diseases: a review of patents and current developments (2006–2010). *Expert Opin Ther Pat* **21**, 1543–1573 (2011).
17. Kuraki, T., Ishibashi, M., Takayama, M., Shiraiishi, M. & Yoshida, M. A novel oral neutrophil elastase inhibitor (ONO-6818) inhibits human neutrophil elastase-induced emphysema in rats. *Am J Respir Crit Care Med* **166**, 496–500 (2002).
18. Tanaka, K. et al. Therapeutic effect of lecithinized superoxide dismutase on pulmonary emphysema. *J Pharmacol Exp Ther* **338**, 810–818 (2011).
19. Tanaka, K., Sato, K., Aoshiba, K., Azuma, A. & Mizushima, T. Superiority of PC-SOD to other anti-COPD drugs for elastase-induced emphysema and alteration in lung mechanics and respiratory function in mice. *Am J Physiol Lung Cell Mol Physiol* **302**, L1250–L1261 (2012).
20. Bergogne-Berezin, E. & Bryskier, A. The suppository form of antibiotic administration: pharmacokinetics and clinical application. *J Antimicrob Chemother* **43**, 177–185 (1999).
21. Sasaki, K., Yonebayashi, S., Yoshida, M., Shimizu, K., Aotsuka, T. & Takayama, K. Improvement in the bioavailability of poorly absorbed glycyrrhizin via various non-vascular administration routes in rats. *Int J Pharm* **265**, 95–102 (2003).
22. Agarwal, R. & Jindal, S. K. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. *Eur J Intern Med* **19**, 227–235 (2008).
23. Verhamme, K. M. et al. Tiotropium Handihaler and the risk of cardio- or cerebrovascular events and mortality in patients with COPD. *Pulm Pharmacol Ther* **25**, 19–26 (2012).
24. Gross, N. J., Giembycz, M. A. & Rennard, S. I. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor. *COPD* **7**, 141–153 (2010).
25. Miravittles, M. & Anzueto, A. Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies. *Int J Chron Obstruct Pulmon Dis* **4**, 185–201 (2009).
26. Rajendrasozhan, S., Yang, S. R., Edirisinghe, I., Yao, H., Adenuga, D. & Rahman, I. Deacetylases and NF-kappaB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD. *Antioxid Redox Signal* **10**, 799–811 (2008).
27. Ito, K. et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. *J Exp Med* **203**, 7–13 (2006).
28. Asano, T. et al. Effects of beta-(1,3-1,6)-D-glucan on irritable bowel syndrome-related colonic hypersensitivity. *Biochem Biophys Res Commun* **420**, 444–449 (2012).
29. McLaughlin, B., Buendia, M. A., Saborido, T. P., Palubinsky, A. M., Stankowski, J. N. & Stanwood, G. D. Haploinsufficiency of the E3 ubiquitin ligase C-terminus of heat shock cognate 70 interacting protein (CHIP) produces specific behavioral impairments. *PLoS One* **7**, e36340 (2012).

Acknowledgments

We thank Dr. Tomoko Betsuyaku (Keio University) for helpful discussion and Mrs. Kumi Matsuura (Kumamoto University) for technical assistance. This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Health, Labour, and Welfare of Japan, as well as the Japan Science and Technology Agency and Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Author contributions

Conception and design: K.T. and T.M.; Analysis and interpretation: K.T., T.A., N.Y., D.K., Y.Y., H.Y., S.K. and T.I.; Drafting the manuscript for important intellectual content: K.T., T.A., N.Y., H.W., T.M., H.S. and T.M.

Additional information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Tanaka, K.-I. et al. Superiority of pulmonary administration of mepenzolate bromide over other routes as treatment for chronic obstructive pulmonary disease. *Sci. Rep.* **4**, 4510; DOI:10.1038/srep04510 (2014).



This work is licensed under a Creative Commons Attribution 3.0 Unported license. To view a copy of this license, visit <http://creativecommons.org/licenses/by/3.0>

Diclofenac Protects Cultured Human Corneal Epithelial Cells Against Hyperosmolarity and Ameliorates Corneal Surface Damage in a Rat Model of Dry Eye

Ryoichi Sawazaki,¹ Tomoaki Ishihara,¹ Shinya Usui,¹ Erika Hayashi,¹ Kayoko Tahara,¹ Tatsuya Hoshino,¹ Akihiro Higuchi,² Shigeru Nakamura,² Kazuo Tsubota,² and Tohru Mizushima¹

¹Department of Analytical Chemistry, Faculty of Pharmacy, Keio University, Tokyo, Japan

²Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan

Correspondence: Tohru Mizushima, Department of Analytical Chemistry, Faculty of Pharmacy, Keio University, 1-5-30, Shibakoen, Minato-ku, Tokyo 105-8512, Japan; mizushima-th@pha.keio.ac.jp.

Submitted: December 28, 2013
Accepted: March 19, 2014

Citation: Sawazaki R, Ishihara T, Usui S, et al. Diclofenac protects cultured human corneal epithelial cells against hyperosmolarity and ameliorates corneal surface damage in a rat model of dry eye. *Invest Ophthalmol Vis Sci*. 2014;55:XXXX-XXXX. DOI:10.1167/iov.13-13850

PURPOSE. Dry eye syndrome (DES) is characterized by an increase in tear osmolarity and induction of the expression and nuclear localization of an osmoprotective transcription factor (nuclear factor of activated T-cells 5 [NFAT5]) that plays an important role in providing protection against hyperosmotic tears. In this study, we screened medicines already in clinical use with a view of finding compounds that protect cultured human corneal epithelial cells against hyperosmolarity-induced cell damage.

METHODS. Viable cell number was determined by the MTT method and cellular NFAT5 level was measured by immunoblotting. The rat model for DES was developed by removal of the lacrimal glands, with an assessment of corneal surface damage based on levels of fluorescein staining and epithelial apoptosis.

RESULTS. Some nonsteroidal anti-inflammatory drugs (NSAIDs), including diclofenac sodium (diclofenac), were identified during the screening procedure. These NSAIDs were able to suppress hyperosmolarity-induced apoptosis and cell growth arrest. In contrast, other NSAIDs, including bromfenac sodium (bromfenac), did not exert such a protective action. Treatment of cells with diclofenac, but not bromfenac, stimulated both the nuclear localization and expression of NFAT5 under hyperosmotic conditions. In the rat model for DES, topical administration of diclofenac (but not bromfenac) to eyes reduced corneal surface damage without affecting the volume of tear fluid.

CONCLUSIONS. Diclofenac appears to protect cells against hyperosmolarity-induced cell damage and NFAT5 would play an important role in this protective action. The findings reported here may also indicate that the topical administration of diclofenac to eyes may be therapeutically beneficial for DES patients.

Keywords: diclofenac, hyperosmolarity, nuclear factor of activated T-cells 5, dry eye syndromes

Dry eye syndrome (DES) is one of the most common ocular disorders, affecting approximately 10% to 20% of the adult population in Western countries and Japan.^{1,2} Due to an increase in time spent using visual display terminals, along with the air-drying effect of air conditioners, and frequent use of contact lenses, the number of DES patients has increased steadily.¹ Although the pathogenesis of DES remains unclear, various factors, such as aging, hormonal changes, environmental factors (noxious and infectious agents), inflammation, and autoimmunity may be involved. Inflammation in particular could play an important role because an increased level of proinflammatory cytokines in tear fluid was reported in DES patients and in animal models; to this extent, some anti-inflammatory agents (such as cyclosporine A and corticosteroids) have been suggested to be therapeutically beneficial for DES patients.^{1,3-7}

DES is associated with a decrease in the volume of tear fluid, which is caused by both a reduction of tear production by the lacrimal glands and enhancement of evaporative tear loss due

to abnormal lipid and mucin profiles, and this abnormality also gives rise to an unstable tear film in DES.^{1,8} These alterations in tear fluid properties cause chronic ocular (both corneal and conjunctive) surface irritation and inflammation, resulting in ocular dryness and discomfort and visual dysfunction, which greatly reduce patient quality of life.

Elevated tear osmolarity is a key pathological factor and also a good biomarker for the diagnosis of DES, given that the extent of increased tear osmolarity has been found to correlate with the condition's severity.^{1,9} In response to elevated tear osmolarity, cells rapidly uptake Na⁺ and other ions to maintain cell volume.¹⁰ However, this enhanced uptake causes a higher intracellular ionic strength, which in turn leads to cell-cycle arrest and the induction of apoptosis, resulting in lacrimal gland dysfunction and damage to the ocular surface. To overcome these disadvantages, an osmoprotective stress response is induced in cells in which nuclear factor of activated T-cells 5 (NFAT5; also known as tonicity enhancer binding protein) plays a central role.¹¹ Although hyperosmolarity

rapidly activates NFAT5, thereby enhancing the latter's nuclear translocation,^{11,12} it also gradually induces the expression of NFAT5.¹³ NFAT5 positively regulates the gene expression of various osmoprotective proteins.¹⁴ Among them, proteins responsible for the synthesis and transport of compatible small organic osmolytes (such as betaine/GABA transporter-1) especially play important roles, as they are able to suppress the increase in intracellular ionic strength by accumulating compatible small organic osmolytes in cells.¹⁵

Patients with DES were previously treated with artificial tear supplementation, which provides only a temporary relief of symptoms. In addition to punctal occlusion and tear replacement therapy, clinical treatment for DES patients has been improved recently by the development of new types of drugs, such as anti-inflammatory agents, sodium hyaluronate, hormones, and secretagogues to stimulate mucin and tear fluid generation (such as rebamipide and diquafosol).^{1,16-19} However, these drugs have drawbacks, such as low efficacy, adverse effects, and the requirement of frequent instillation. Difficulties therefore remain for eye-care professionals to manage moderate-to-severely affected DES patients. Thus, the development of DES drugs with novel mechanisms of action is required.

Recent studies have revealed that hyperosmolarity-induced ocular epithelial cell apoptosis plays an important role in the pathogenesis of DES.^{20,21} Ocular epithelial cell apoptosis reduces the mucin layer, which in turn stimulates evaporative tear loss. To this end, accelerated ocular epithelial cell apoptosis was observed in DES patients and in animal models of DES.²²⁻²⁵ Furthermore, in line with an improvement of DES symptoms in response to treatment with cyclosporine A, a decrease in ocular epithelial cell apoptosis was observed in DES patients.²⁴ Although compounds that protect ocular epithelial cells against hyperosmolarity may serve as good candidates for DES drugs, such compounds have not yet been identified.

In the present study, we used a library of approved medicines to screen for compounds that protect cultured human corneal epithelial (HCE) cells from hyperosmolarity-induced cell damage, with diclofenac sodium (diclofenac) identified as a potential candidate drug. Diclofenac is a commonly used nonsteroidal anti-inflammatory drug (NSAID). The findings from this study suggest that diclofenac suppresses hyperosmolarity-induced apoptosis and cell growth arrest in a process mediated both by the nuclear translocation of NFAT5 and induction of its expression. In a rat model for dry eye, topical administration of diclofenac to eyes reduced damage to the ocular surface and suppressed ocular epithelial cell apoptosis. These results suggest that the topical administration of diclofenac to eyes could serve as a good candidate therapy for DES patients.

MATERIALS AND METHODS

Materials, Assay for Caspase Activity, Real-time RT-PCR Analysis, BrdU Incorporation Assay, Immunoblotting Analysis, TdT-mediated Biotinylated UTP Nick End Labeling (TUNEL), and Immunohistochemical Analyses

Details are shown in the Supplementary material.

Cell Culture

A human SV-40 immortalized corneal epithelial cell line (RCB 2280) was obtained from the Riken Bioresource Cell Bank (Ibaraki, Japan) and used as HCE cells in this study. HCE cells were cultured in a mixture of Dulbecco's modified Eagle's

medium and Nutrient Mixture F-12 medium, supplemented with 5% fetal bovine serum, 10 ng/mL epidermal growth factor, 1 μ g/mL insulin, 100 U/mL penicillin, and 100 μ g/mL streptomycin in a humidified atmosphere of 95% air with 5% CO₂ at 37°C.

To examine the effect of NSAIDs on hyperosmolarity-dependent cell damage, cells (8×10^4 cells/24-well plate or 1×10^6 cells/100-mm dish, about 50% confluent) were exposed to hyperosmolarity by changing the entire bathing medium into that containing high concentration of each chemical (150 mM NaCl, 280 mM glucose or sorbitol; approximately 600 mOsm/L) and/or NSAID. Viable cell number was determined by the MTT method.²⁶ Briefly, cells were incubated for 2 hours with MTT solution at a final concentration of 0.5 mg/mL. Isopropanol and hydrochloric acid were added to the culture medium at final concentrations of 50% and 20 mM, respectively. The optical density of each sample at 570 nm was determined spectrophotometrically by using a reference wavelength of 630 nm.

Determination of prostaglandin E₂ (PGE₂) level in the culture media was done by EIA, as previously described.²⁶

Analysis With the Rat Model for Dry Eye

All animal experiments were approved by the Laboratory Animal Care and Use Committee of Keio University. All studies adhered to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

Six-week-old male Sprague-Dawley rats were purchased from Charles River Laboratories Japan, Inc. (Kanagawa, Japan). The rat model for dry eye was prepared by removing the lacrimal glands.²⁷ Administration of NSAID to two eyes (three times daily) was done from 1 to 5 weeks after the removal of lacrimal glands. To estimate the degree of corneal surface damage at 5 weeks after the removal of lacrimal glands, 2 μ L 0.05% fluorescein in PBS was instilled into the inferior conjunctival sac and the corneal surface was photographed. The fluorescein score was estimated as described previously.²⁸ Briefly, the photographic image was divided into nine areas and the degree of fluorescein staining in each area was scored from 0 to 3 points according to the criteria described previously²⁸ by an observer unaware of the treatment that the animals had received. The scores for all areas were summed to obtain the overall fluorescein score.

Tear volume was measured by cotton thread (ZONE-QUICK; Showa Yakuhin Kako Co., Ltd., Tokyo, Japan), according to the standard procedure used for clinical practice.²⁹

Statistical Analysis

All values were expressed as the mean \pm SEM or SD. One-way ANOVA followed by the Tukey test was used to evaluate differences between more than three groups. Differences were considered to be significant for values of *P* less than 0.05.

RESULTS

Diclofenac-Dependent Protection Against Hyperosmolarity-Induced Cell Damage

From a library of medicines already in clinical use, we screened for compounds able to suppress hyperosmolarity-induced cell damage in HCE cells; cells were treated with each drug under hyperosmotic conditions (150 mM NaCl, approximately 600 mOsm/L) and the viable cell number was determined by the MTT method. Among candidate compounds selected by this screening procedure, we focused on two NSAIDs (diclofenac

and etodolac) and examined the dose-response profile for the effects of these and other NSAIDs on hyperosmolarity-induced cell damage. As shown in Figure 1A, in addition to diclofenac and etodolac, meloxicam, indomethacin, acetaminophen, celecoxib, and rofecoxib showed protective effects against hyperosmolarity-induced cell damage. On the other hand, other NSAIDs, including bromfenac, whose inhibitory effect on COX is similar to that of diclofenac,³⁰ did not exert any such protective action (Fig. 1A). Treatment of cells with diclofenac also reduced the cell damage induced by hyperosmolarity due to a high concentration of glucose or sorbitol (Fig. 1B).

The results in Figure 1 suggest that diclofenac affects the cell death (apoptosis) and/or cell growth arrest caused by a hyperosmotic shock. As shown in Figure 2A, treatment of cells with diclofenac (but not bromfenac) suppressed the hyperosmolarity-induced activation of caspase-3-like activity, suggesting that diclofenac could suppress apoptosis induced by this treatment. On the other hand, cell growth under hyperosmotic conditions was also restored by the treatment of cells with diclofenac, but not bromfenac (Fig. 2B). These results suggest that diclofenac protects cells against damage produced by hyperosmolarity by suppressing both apoptosis and cell growth arrest.

NSAID achieves its anti-inflammatory effects through the inhibition of cyclo-oxygenase (COX), an enzyme that is essential for the synthesis of PGE₂, a strong inducer of inflammation. To test the contribution of COX inhibition by diclofenac to this protective action, we examined the effect of exogenously added PGE₂ on viable cell number in the presence of diclofenac under hyperosmotic conditions. As shown in Figure 3A, exogenously added PGE₂ (even at concentrations much higher than the endogenous level (6.9 nM, based on data in Fig. 3B) did not affect the viable cell number, suggesting that the protective effect of diclofenac against cell damage induced by hyperosmolarity cannot be explained by its inhibitory effect on COX and a resulting decrease in the level of PGE₂. We also compared the dose-response profiles of diclofenac in terms of the decrease in the PGE₂ level and the protective effect against hyperosmolarity-induced cell damage. As shown in Figures 3B and 3C, 0.1 nM diclofenac was required to decrease the PGE₂ level, whereas 100 nM was necessary to protect against the cell damage caused by hyperosmolarity. The results in Figures 3B and 3C also show that although 0.1 nM bromfenac decreased the PGE₂ level, this drug did not protect cells against hyperosmolarity at any of the concentrations tested (from 0.1 nM to 1 μM). These findings support the idea that treatment of cells with diclofenac protects against hyperosmolarity-induced cell damage in a manner that is independent of COX inhibition and a subsequent decrease in the level of PGE₂.

Involvement of NFAT5 in Diclofenac-Dependent Protection Against Hyperosmolarity-Induced Cell Damage

To understand the mechanism for diclofenac-dependent protection against hyperosmolarity-induced cell damage, we first monitored the cellular level of NFAT5 under hyperosmotic conditions. As shown in Figure 4A, cells cultured under hyperosmotic conditions for 6 hours exhibited an increased level of NFAT5, as described previously.¹³ Furthermore, we found that treatment of cells with diclofenac (but not bromfenac) increased the cellular level of NFAT5 under hyperosmotic conditions, but not under isotonic conditions (approximately 300 mOsm/L) (Fig. 4A).

As it was reported that cells cultured under hyperosmotic conditions rapidly activate NFAT5 to stimulate its nuclear localization,¹² we next examined the effect of diclofenac on

the nuclear localization of NFAT5 under our experimental conditions. As shown in Figure 4B, cells cultured under hyperosmotic conditions for 1 hour showed increased levels of NFAT5 in nuclear fractions but not in whole-cell fractions, suggesting that the nuclear localization of NFAT5 was stimulated by the hyperosmotic conditions. The results in Figure 4B also suggest that the treatment of cells with diclofenac (but not bromfenac) stimulates the nuclear localization of NFAT5 under hyperosmotic conditions but not under isotonic conditions.

To examine the activity of NFAT5 in cultured cells, we monitored the mRNA expression of *bgt1*. Figure 4C shows that the mRNA expression of *bgt1* was upregulated in cells cultured under hyperosmotic conditions, as described previously.¹⁴ Furthermore, treatment of cells with diclofenac (but not bromfenac) for 6 hours upregulated the *bgt1* mRNA expression under hyperosmotic conditions but not under isotonic conditions (Fig. 4C). Taken together, these results suggest that, under hyperosmotic conditions, the treatment of cells with diclofenac stimulates both the expression and nuclear localization of NFAT5, which in turn exerts a protective effect against the hyperosmolarity-induced cell damage via an increase in the activity of NFAT5.

It was reported that HCE cells treated with hyperosmolarity increase inflammatory cytokines (such as TNF-α) and MMPs (such as MMP-9)^{15,31} and we here examined the effect of diclofenac on hyperosmolarity-dependent upregulation of expression of TNF-α and MMP-9. As shown in Figures 4D and 4E, cells cultured under hyperosmotic conditions exhibited the upregulation of mRNA expression of *tnf-α* and *mmp-9* and simultaneous treatment of cells with diclofenac suppressed this induction.

Diclofenac-Dependent Amelioration of Corneal Surface Damage in a Rat Model of Dry Eye

On a rat model of dry eye produced by the removal of lacrimal glands, we examined if the topical administration of diclofenac (or bromfenac) to eyes reduced the extent of corneal surface damage. The three times daily topical administration of diclofenac (or bromfenac) to eyes was commenced 1 week after the removal of lacrimal glands, and corneal surface damage, assessed as a function of the intensity of fluorescein staining, was measured a further 4 weeks later. The volume of tear fluid was lower in rats subjected to lacrimal gland removal than sham-operated rats at both 1 and 5 weeks after the surgical intervention (Fig. 5A).

As shown in Figures 5B and 5C, the removal of lacrimal glands increased the level of fluorescein staining at the corneal surface, thus demonstrating that the intervention resulted in corneal surface damage. The topical administration of diclofenac (but not bromfenac) clearly suppressed this increase in the level of staining (Figs. 5B, 5C). We also examined the level of corneal epithelial cell death by TUNEL assay. The topical administration of diclofenac (but not bromfenac) decreased the number of TUNEL-positive corneal epithelial cells in this rat model (Figs. 5D, 5E). It was confirmed that diclofenac (or bromfenac) did not further affect the volume of tear fluid in rats subjected to lacrimal gland removal (Fig. 5A). We also examined the effect of topical administration of diclofenac (or bromfenac) on expression of NFAT5. Immunohistochemical analysis with an antibody against NFAT5 showed that the level of NFAT5 at the corneal surface was increased by the topical administration of diclofenac (but not bromfenac) (Figs. 5F, 5G) in the rat dry eye model. In summary, these results in Figure 5 suggest that the topical administration of diclofenac to eyes suppresses the corneal surface damage produced by the removal of lacrimal glands, but without affecting the tear fluid volume.




FIGURE 1. Effects of different NSAIDs on hyperosmolarity-induced cell damage. HCE cells were incubated with the indicated concentration of each NSAID in the presence of 150 mM NaCl (A) or 280 mM glucose or sorbitol (B) for 24 hours. Viable cell number was determined by the MTT method and expressed relative to control (isotonic conditions) absorbance value. Values are mean ± SD, n = 3. *P < 0.05; **P < 0.01.

DISCUSSION

DES affects the quality of life of a large number of people around the world. As clinical protocols have not yet been established, there is scope for new types of drugs to be developed. Although it is clear that hyperosmolarity-induced

ocular epithelial cell apoptosis plays an important role in the pathogenesis of DES, drugs that could suppress this apoptosis have not been identified at present. To address this issue, we tried to screen for such compounds.

Diclofenac eye drops are widely used for the treatment of ocular inflammation, such as keratitis, conjunctivitis, uveitis,




FIGURE 2. Effects of different NSAIDs on hyperosmolarity-induced apoptosis and cell growth arrest. HCE cells were incubated with the indicated concentration of each NSAID in the presence or absence of 150 mM NaCl for 6 hours (A) or 12 hours (B). Caspase-3-like activity was measured using fluorogenic peptide substrates (A). Cell growth was monitored by the BrdU incorporation assay and expressed relative to control (isotonic conditions) value (B). Values are mean \pm SD, $n = 5$. * $P < 0.05$; ** $P < 0.01$.

and postoperative inflammation.^{32,33} Compared with corticosteroids and cyclosporine A, topical administration of diclofenac to eyes has certain safety advantages, being free of the adverse effects associated with the use of corticosteroids (such as an increase in IOP, lens opacification, and cataractogenesis) or cyclosporine A (such as burning symptoms and conjunctival hyperemia).^{4,17,34} It was reported that the level of PGE₂ in tear fluid was increased in DES patients compared with healthy volunteers, and that some NSAIDs (such as bromfenac sodium [bromfenac]) were found to be effective suppressors of inflammation associated with DES.³⁵ These results suggest that the topical administration of diclofenac to eyes may be a good candidate therapy for DES; however, such idea had not been tested.

We here found that treatment with diclofenac protected cultured HCE cells against hyperosmolarity-induced cell damage via the suppression of both apoptosis and cell growth arrest. This protective effect was not, however, observed for the other NSAIDs tested and there was no evident relationship between protective effects and the capacity of NSAIDs to inhibit COX activity or of their COX-1/COX-2 selectivity (COX-2-selective NSAIDs are celecoxib, rofecoxib, and meloxicam;

COX-1-selective NSAID is SC-560). These findings suggested that diclofenac suppresses hyperosmolarity-induced cell damage independently of COX inhibition accompanied by a decrease in the level of PGE₂. The following evidence was obtained in support of this conclusion: (1) exogenously added PGE₂ did not affect the viable cell number, even at concentrations much higher than the endogenous level, in the presence of diclofenac under hyperosmotic conditions; (2) the dose-response profiles of diclofenac describing its protective effect against hyperosmolarity-induced cell damage was not correlated with that of the decrease in the level of PGE₂; and (3) although bromfenac decreased the PGE₂ level in a similar way to that of diclofenac, it did not protect against hyperosmolarity-induced cell damage.

It was previously reported that cells respond to hyperosmotic stress via the NFAT5-mediated induction of expression of various genes (such as transporters of compatible small organic osmolytes); this induction is mediated by stimulation of both the expression and nuclear localization of NFAT5.¹¹⁻¹³ We found here that treatment of cells with diclofenac for 1 hour stimulated the nuclear localization of NFAT5 and that treatment for 6 hours stimulated the expression of NFAT5 under




FIGURE 3. Independence on COX inhibition of the protective effect of diclofenac against hyperosmolarity-induced cell damage. HCE cells were incubated with the indicated concentration of PGE₂ (A), diclofenac (A, C), and bromfenac (C) in the presence of 150 mM NaCl for 24 hours. Viable cell number was determined by the MTT method and expressed relative to control (isotonic conditions) absorbance value. (B) HCE cells were preincubated with the indicated concentration of diclofenac or bromfenac for 30 minutes and further incubated with 10 μM arachidonic acid for 30 minutes in the presence of the same concentration of each NSAID as in the preincubation step. The amount of PGE₂ in the culture medium was determined by EIA. Values are mean ± SD, n = 3. *P < 0.05; **P < 0.01.

hyperosmotic conditions. We also found that treatment of cells with diclofenac upregulated the expression of *bgt1* mRNA. We consider that the diclofenac-dependent stimulation of both the expression and nuclear localization of NFAT5 is involved in the activation of NFAT5 transcriptional activity. In addition to the

fact that bromfenac did not provide a protective effect against hyperosmolarity-induced cell damage, it was not able to stimulate the expression of NFAT5 or its nuclear localization, or increase *bgt1* mRNA expression. These findings suggest that these phenomena play important roles in the protection




FIGURE 4. Effect of diclofenac on the expression and nuclear translocation of NFAT5. HCE cells were incubated with the indicated concentration of diclofenac (A–E) or bromfenac (A–C) in the presence or absence of 150 mM NaCl for 6 hours (A, C), 1 hour (B), 12 hours (D), or 24 hours (E). Whole-cell extracts (A, B) or nuclear extracts (B) were analyzed by immunoblotting with an antibody against NFAT5, actin, or lamin B (A, B). The intensity of the NFAT5 band was determined and expressed relative to the control (isotonic conditions without NSAID) value (A, B). The relative expression of *bgt1* (C), *tnfr* (D), or *mmp-9* (E) mRNA was monitored by real-time RT-PCR. (C–E) Values normalized to *actin* expression were expressed relative to the control (isotonic conditions without NSAID) value. Values are mean ± SD, *n* = 3. **P* < 0.05; ***P* < 0.01.

shown by diclofenac against hyperosmolarity-induced cell damage. It should be noted that diclofenac affected neither the expression nor nuclear localization of NFAT5 under normal osmotic conditions. Thus, it seems that diclofenac specifically affects cells exposed to hyperosmotic stress, which is an

interesting outcome considering its possible clinical application for the treatment of DES patients.

In the rat model for DES, the topical administration of diclofenac (0.1%) to eyes suppressed the corneal surface damage caused by removal of the lacrimal glands without




FIGURE 5. Effects of diclofenac eye drops on corneal surface damage in rats. The rat model of dry eye was developed by the removal of lacrimal glands, and the diclofenac or bromfenac treatment was administered from weeks 1 to 5 after removal. (A–G) Diclofenac (0.1%, 3.1 mM), bromfenac (0.1%, 2.6 mM), or vehicle (the same buffer without NSAID) eye drops (5 μ L) were administered three times daily. (A) The volume of tear fluid was measured according to cotton thread test. (B) Images of fluorescein-stained cornea are shown. (C) Fluorescein score was calculated as described in materials and methods. (C–G) Sections of eye tissues were prepared 5 weeks after lacrimal gland removal. (D) Sections were subjected to TUNEL assay and DAPI staining (scale bar: 50 μ m). (E) The number of TUNEL-positive cells was counted. (F) Immunohistochemical analysis with an antibody to NFAT5 was performed (scale bar: 50 μ m). (G) The relative fluorescence intensity was determined. Values are mean \pm SEM. * P < 0.05; ** P < 0.01.

76

affecting the tear fluid volume. Furthermore, administration of bromfenac by the same protocol did not reduce the damage. In agreement with our in vitro results, these results suggest that diclofenac suppressed corneal surface damage by protecting the corneal epithelial cells against hyperosmolarity-induced damage. As diclofenac eye drops (0.1%) have been used for the treatment of ocular inflammation,^{32,33} the safety of this treatment approach has thus already been confirmed in humans. This provides diclofenac with a distinct advantage for its clinical use to treat DES compared with new agents that have yet to be clinically tested or approved.

A concern for use of diclofenac eye drops is corneal melting.^{36,37} We reported that topical administration of diclofenac for 2 months was free from significant abnormality in corneal epithelial structure and function in patients with healthy corneas, but this topical administration caused significant abnormality in some patients with refractive surgery.^{38,39} However, as the pathogenesis of diclofenac (or other NSAID)-induced corneal melting is unclear at present, we could not predict the risk of diclofenac-dependent corneal melting in DES patients. Therefore, at the clinical study to test the efficacy of diclofenac eye drops on DES patients, corneal melting should be paid much attention.

As described in the introduction, inflammation plays an important role in the corneal surface damage associated with DES. Thus, the ineffectiveness of bromfenac eye drops to combat corneal surface damage induced by the removal of the lacrimal glands is surprising. We consider that this is because inflammation was not induced in this animal model of dry eye under the conditions used. In fact, we found that the mRNA expression of proinflammatory cytokines (such as TNF- α) was not induced in the eyes of rats subjected to lacrimal gland removal (data not shown). An absence of inflammatory responses was also reported in a monkey model of dry eye induced by lacrimal gland removal.⁴⁰ On the other hand, the anti-inflammatory effect of NSAIDs could be effective in suppressing inflammation associated with DES in humans. For example, a phase 2 clinical study of bromfenac eye drops to treat DES noted the efficacy of this drug.⁴¹ Thus, the advantage of diclofenac eye drops to treat DES is that this drug not only has anti-inflammatory effects but also cytoprotective actions. On this basis, we propose that diclofenac eye drops could be therapeutically beneficial for DES patients.

Acknowledgments

Supported by Grants-in-Aid for Scientific Research from the Ministry of Health, Labour, and Welfare of Japan.

Disclosure: R. Sawazaki, None; T. Ishihara, None; S. Usui, None; E. Hayashi, None; K. Tahara, None; T. Hoshino, None; A. Higuchi, None; S. Nakamura, None; K. Tsubota, None; T. Mizushima, None

References

1. Research in dry eye: report of the Research Subcommittee of the International Dry Eye Workshop. *Ocul Surf.* 2007;5:179-193.
2. Uchino M, Dogru M, Yagi Y, et al. The features of dry eye disease in a Japanese elderly population. *Optom Vis Sci.* 2006;83:797-802.
3. Yoon KC, Jeong IY, Park YG, Yang SY. Interleukin-6 and tumor necrosis factor- α levels in tears of patients with dry eye syndrome. *Cornea.* 2007;26:431-437.
4. Pflugfelder SC. Antiinflammatory therapy for dry eye. *Am J Ophthalmol.* 2004;137:337-342.
5. Zhu L, Zhang C, Chuck RS. Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model. *Mol Vis.* 2012;18:1803-1812.
6. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. *Am J Ophthalmol.* 2004;138:444-457.
7. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. *Invest Ophthalmol Vis Sci.* 2001;42:2283-2292.
8. Shimazaki-Den S, Dogru M, Higa K, Shimazaki J. Symptoms, visual function, and mucin expression of eyes with tear film instability. *Cornea.* 2013;32:1211-1218.
9. Liu H, Begley C, Chen M, et al. A link between tear instability and hyperosmolarity in dry eye. *Invest Ophthalmol Vis Sci.* 2009;50:3671-3679.
10. Ho SN. Intracellular water homeostasis and the mammalian cellular osmotic stress response. *J Cell Physiol.* 2006;206:9-15.
11. Burg MB, Ferraris JD, Dmitrieva NI. Cellular response to hyperosmotic stresses. *Physiol Rev.* 2007;87:1441-1474.
12. Izumi Y, Li J, Villers C, Hashimoto K, Burg MB, Ferraris JD. Mutations that reduce its specific DNA binding inhibit high NaCl-induced nuclear localization of the osmoprotective transcription factor NFAT5. *Am J Physiol Cell Physiol.* 2012;303:C1061-C1069.
13. Lee JH, Kim M, Im YS, Choi W, Byeon SH, Lee HK. NFAT5 induction and its role in hyperosmolar stressed human limbal epithelial cells. *Invest Ophthalmol Vis Sci.* 2008;49:1827-1835.
14. Tsai TT, Danielson KG, Guttapalli A, et al. TonEBP/OREBP is a regulator of nucleus pulposus cell function and survival in the intervertebral disc. *J Biol Chem.* 2006;281:25416-25424.
15. Garrett Q, Khandekar N, Shih S, et al. Betaine stabilizes cell volume and protects against apoptosis in human corneal epithelial cells under hyperosmotic stress. *Exp Eye Res.* 2013;108:33-41.
16. Kinoshita S, Oshiden K, Awamura S, Suzuki H, Nakamichi N, Yokoi N. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye. *Ophthalmology.* 2013;120:1158-1165.
17. Skaliky SE, Petsoglou C, Gurbaxani A, Fraser CL, McCluskey P. New agents for treating dry eye syndrome. *Curr Allergy Asthma Rep.* 2013;13:322-328.
18. Doughty MJ, Glavin S. Efficacy of different dry eye treatments with artificial tears or ocular lubricants: a systematic review. *Ophthalmic Physiol Opt.* 2009;29:573-583.
19. Takamura E, Tsubota K, Watanabe H, Ohashi Y. A randomized, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. *Br J Ophthalmol.* 2012;96:1310-1315.
20. Luo L, Li DQ, Pflugfelder SC. Hyperosmolarity-induced apoptosis in human corneal epithelial cells is mediated by cytochrome c and MAPK pathways. *Cornea.* 2007;26:452-460.
21. Wang L, Dai W, Lu L. Hyperosmotic stress-induced corneal epithelial cell death through activation of Polo-like kinase 3 and c-Jun. *Invest Ophthalmol Vis Sci.* 2011;52:3200-3206.
22. Yeh S, Song XJ, Farley W, Li DQ, Stern ME, Pflugfelder SC. Apoptosis of ocular surface cells in experimentally induced dry eye. *Invest Ophthalmol Vis Sci.* 2003;44:124-129.
23. Chen W, Zhang X, Liu M, et al. Trehalose protects against ocular surface disorders in experimental murine dry eye through suppression of apoptosis. *Exp Eye Res.* 2009;89:311-318.

24. Brignole F, Pisella PJ, De Saint Jean M, Goldschild M, Goguel A, Baudouin C. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. *Invest Ophthalmol Vis Sci.* 2001;42:90-95.
25. Chen W, Zhang X, Li J, et al. Efficacy of osmoprotectants on prevention and treatment of murine dry eye. *Invest Ophthalmol Vis Sci.* 2013;54:6287-6297.
26. Yamakawa N, Suemasu S, Kimoto A, et al. Low direct cytotoxicity of loxoprofen on gastric mucosal cells. *Biol Pharm Bull.* 2010;33:398-403.
27. Fujihara T, Murakami T, Fujita H, Nakamura M, Nakata K. Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. *Invest Ophthalmol Vis Sci.* 2001;42:96-100.
28. Higuchi A, Inoue H, Kawakita T, Ogishima T, Tsubota K. Selenium compound protects corneal epithelium against oxidative stress. *PLoS One.* 2012;7:e45612.
29. Higuchi A, Takahashi K, Hirashima M, Kawakita T, Tsubota K. Selenoprotein P controls oxidative stress in cornea. *PLoS One.* 2010;5:e9911.
30. Reddy R, Kim SJ. Critical appraisal of ophthalmic ketorolac in treatment of pain and inflammation following cataract surgery. *Clin Ophthalmol.* 2011;5:751-758.
31. Li DQ, Chen Z, Song XJ, Luo L, Pflugfelder SC. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. *Invest Ophthalmol Vis Sci.* 2004;45:4302-4311.
32. Goa KL, Chrisp P. Ocular diclofenac. A review of its pharmacology and clinical use in cataract surgery, and potential in other inflammatory ocular conditions. *Drugs Aging.* 1992;2:473-486.
33. Palmero M, Bellot JL, Alcoriza N, Garcia-Cabanes C, Orts A. The ocular pharmacokinetics of topical diclofenac is affected by ocular inflammation. *Ophthalmic Res.* 1999;31:309-316.
34. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. *Ophthalmology.* 2000;107:631-639.
35. Shim J, Park C, Lee HS, et al. Change in prostaglandin expression levels and synthesizing activities in dry eye disease. *Ophthalmology.* 2012;119:2211-2219.
36. Hsu JK, Johnston WT, Read RW, et al. Histopathology of corneal melting associated with diclofenac use after refractive surgery. *J Cataract Refract Surg.* 2003;29:250-256.
37. Lin JC, Rapuano CJ, Laibson PR, Eagle RC Jr, Cohen EJ. Corneal melting associated with use of topical nonsteroidal anti-inflammatory drugs after ocular surgery. *Arch Ophthalmol.* 2000;118:1129-1132.
38. Shimazaki J, Fujishima H, Yagi Y, Tsubota K. Effects of diclofenac eye drops on corneal epithelial structure and function after small-incision cataract surgery. *Ophthalmology.* 1996;103:50-57.
39. Shimazaki J, Saito H, Yang HY, Toda I, Fujishima H, Tsubota K. Persistent epithelial defect following penetrating keratoplasty: an adverse effect of diclofenac eyedrops. *Cornea.* 1995;14:623-627.
40. Maitchouk DY, Beuerman RW, Ohta T, Stern M, Varnell RJ. Tear production after unilateral removal of the main lacrimal gland in squirrel monkeys. *Arch Ophthalmol.* 2000;118:246-252.
41. Fahmy AM, Hardten DR. Treating ocular surface disease: new agents in development. *Clin Ophthalmol.* 2011;5:465-472.

Queries for iovs-55-04-06

1. Author: This article has been lightly edited for grammar, style, and usage. Please compare against your original document and make changes on these pages. Please limit your corrections to substantive changes that affect meaning. If no change is required in response to a question, please write "OK as set" in the margin. Copy editor
2. Author: Carefully check the spelling and order of the author names and check the affiliations for all of the authors.
3. Author: Make sure that ALL funding/financial support is listed in the information following the Acknowledgments.
4. Author: Please confirm wording of précis: From medicines in clinical use, we screened compounds that protect corneal cells against hyperosmolarity-induced damage and found diclofenac. In the rat model for dry eye, topical administration of diclofenac reduced corneal surface damage, suggesting that this drug is therapeutically beneficial. Copy editor
5. Author: Materials and Methods, Cell Culture: Please define MTT and EIA. Copy editor
6. Author: Figure 5: nonsignificant is never-expand abbreviation per journal style, but per style it should be "NS." Please make the changes to the figure. The definition has been deleted from the figure caption. Copy editor

